Akademik Veri Yönetim Sistemi
İstanbul Tıp Fakültesi Dergisi, cilt.86, sa.2, ss.109-116, 2023 (Hakemli Dergi)
Objective: Overactive bladder (OAB) syndrome is common in women and negatively affects their quality of life. Our study aimed to evaluate the effect of intravesical onabotulinum toxin A injection on quality of life and urinary symptoms in patients with treatment resistant OAB syndrome. Material and Method: The treatment records of 20 patients with treatment-resistant OAB were reviewed. The patients were injected with a 1:1 solution of saline and 100 units of onabotulinum toxin A at 20 different points on the body, avoiding the bladder trigon. The following survey instruments were used to determine the patient’s quality of life before and after treatment: the King’s Health Questionnaire (KHQ), the short-form Urodistress Inventory (UDI 6), the short-form Incontinence Impact Questionnaire (IIQ 7), the International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms Modules (ICIQ FLUTS), the Female Sexual Function Index (FSFI), and the Pelvic Organ Prolapse/Urinary Incontinence Inquiry form (PISQ-12). The pre-and post-treatment results of the questionnaires were then evaluated. Result: The uroflowmetry parameters indicated that the patients’ maximum urine flow rate decreased significantly after treatment, as did their KHQ scores on all but one item. Evaluation of their FSFI scores indicated no significant change after treatment; however, the other quality of life questionnaires used (UDI-6, IIQ-7, ICIQ-FLUTS, and PISQ-12) revealed significant decreases, indicating an improvement in quality of life. Conclusion: When the patients’ short-term results were evaluated, it was found that this therapy reduced their symptoms and complaints, thus improving their quality of life. Although none of the patients in the sample group experienced complications, in some cases catheterization is necessary due to infection and increased residual urine. Intravesical onabotulinum toxin A injection is a cheap and easy-to-administer treatment for OAB that has not responded to other treatments and does not cause serious side effects.